Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 1994-2002

  Yamanegi, Koji ^a   Kawabe, Mutsuki ^a   Futani, Hiroyuki ^a   Nishiura, Hiroshi ^a   Yamada, Naoko ^a   Kato Kogoe, Nahoko ^a   Kishimoto, Hiromitsu ^a   Yoshiya, Shinichi ^a   Nakasho, Keiji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

HDAC inhibitor; Osteosarcoma; Valproic acid; Vascular endothelial growth inhibitor

Indexed keywords

DEATH RECEPTOR 3; DECOY RECEPTOR 3; TRICHOSTATIN A; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TNFSF15 PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CAPILLARY ENDOTHELIAL CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MEDIATOR; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; OSTEOSARCOMA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; VALPROIC ACID;

EID: 84925428181     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2924     Document Type: Article

References (32)

1. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop Surg 17: 515-527, 2009.
2. Shen H and Laird PW: Interplay between the cancer genome and epigenome. Cell 153: 38-55, 2013.
3. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
4. Ferguson LR, Tatham AL, Lin Z and Denny WA: Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets 11: 199-212, 2011.
5. Rogawski MA and Löscher W: The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5: 553-564, 2004.
6. Bialer M: Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53 (Suppl 7): S26-S33, 2012.
7. Dickinson M, Johnstone RW and Prince HM: Histone deacetylase inhibitors: Potential targets responsible for their anticancer effect. Invest New Drugs 28 (Suppl 1): S3-S20, 2010.
8. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G and Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
9. Zhai Y, Ni J, Jiang GW, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
10. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
11. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S and Li LY: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16: 742-744, 2002.
12. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen S-F and Zhou JXH: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
13. Grimaldo S, Tian F and Li LY: Sensitization of endothelial cells to VEGI-induced apoptosis by inhibiting the NF-kappaB pathway. Apoptosis 14: 788-795, 2009.
14. Ge Z, Sanders AJ, Ye L and Jiang WG: Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2: 167-172, 2011.
15. Liang PH, Tian F, Lu Y, Duan B, Stolz DB and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis 14: 61-68, 2011.
16. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J and Dixit VM: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274: 990-992, 1996.
17. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL and Lin WW: Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64: 1122-1129, 2004.
18. Hou W, Medynski D, Wu S, Lin X and Li LY: VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11: 5595-5602, 2005.
19. Zhang Z and Li LY: TNFSF15 modulates neovascularization and inflammation. Cancer Microenviron 5: 237-247, 2012.
20. Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee JM: Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388: 913-920, 2005.
21. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
22. Bai C, Connolly B, Metzker ML, et al: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97: 1230-1235, 2000.
23. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T and Nakajima Y: The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68, 2002.
24. Ge Z, Sanders AJ, Ye L, Wang Y and Jiang WG: Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro. J Exp Ther Oncol 9: 109-118, 2011.
25. Zong L, Chen P and Wang DX: Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. World J Gastroenterol 20: 4440-4445, 2014.
26. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P and Pili R: Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814-8821, 2006.
27. Kong X, Lin Z, Liang D, Fath D, Sang N and Caro J: Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2028, 2006.
28. Kang FW, Que L, Wu M, Wang ZL and Sun J: Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol Rep 28: 193-199, 2012.
29. Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, Zhang R, Zhang S and Wu G: Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. Int J Oncol 44: 451-458, 2014.
30. Xiao T, Fan JK, Huang HL, Gu JF, Li LY and Liu XY: VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res 20: 367-378, 2010.
31. Mück C, Herndler-Brandstetter D, Micutkova L, Grubeck- Loebenstein B and Jansen-Dürr P: Two functionally distinct isoforms of TL1A (TNFSF15) generated by differential ectodomain shedding. J Gerontol A Biol Sci Med Sci 65: 1165-1180, 2010.
32. Yamanegi K, Yamane J, Kobayashi K, et al: Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 28: 1585-1590, 2012.